Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Гастрит и дуоденит

Список литературы

  1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390):1311-1315. doi: 10.1016/s0140-6736(84)91816-6.
  2. Kusters J.G., van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. ClinMicrobiolRev. 2006; 19(3):449-490.  doi:10.1128/CMR.00054-05.
  3. Graham D.Y., Opekun A.R., Osato M.S., El-Zimaity H.M., Lee C.K., Yamaokaet Y. et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut. 2004; 53(9): 1235-1243. doi: 10.1136/gut.2003.037499.
  4. Ansari S., Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019; 11(11):677. doi: 10.3390/toxins11110677.
  5. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Young H.A., Herrera J., Lissowska J., Yuan C.C., Rothman N., Lanyon G., Martin M., Fraumeni J.F. Jr., Rabkin C.S. Interleukin-1 polymorphisms associated with increased risk of gastric cancer.Nature. 2000; 404(6776):398-402. doi: 10.1038/35006081.
  6. Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P., Liou J.M., Schulz C., et al.; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745.
  7. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S. et al. Kyoto global consensus report on Helicobacter pylorigastritis Gut 2015;64:1353–1367. doi: 10.1136/gutjnl-2015-309252.
  8. Ивашкин В.Т., Маев И.В., Каприн А.Д., Агапов М.Ю., Андреев Д.Н., Водолеев А.С., и соавт. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Рос журн гастроэнтерол гепатол колопроктол. 2019;29(5):53–74. doi:10.22416/1382-4376-2019-29-5-53-74. Ivashkin V.T., Mayev I.V., Kaprin A.D., Agapov M.Yu., Andreev D.N., Vodoleev A.S., et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Rus J Gastroenterol Hepatol Coloproctol. 2019;29(5):53-74. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-5-53-74
  9. Ивашкин В.Т., Лапина Т.Л., Маев И.В., Драпкина О.М., Козлов Р.С., Шептулин А.А., и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):72-93. https://doi.org/10.22416/1382-4376-2022-32-6-72-93 Ivashkin V.T., Lapina T.L., Maev I.V., Drapkina O.M., Kozlov R.S., Sheptulin A.A., et al Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93. https://doi.org/10.22416/1382-4376-2022-32-6-72-93
  10. Симаненков В.И., Маев И.В., Ткачева О.Н, Алексеенко С.А., Андреев Д.Н., Бордин Д.С. и соавт. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. doi:10.15829/1728-8800-2021-2758. Simanenkov V.I., Maev I.V., Tkacheva O.N., Alekseenko S.A., Andreev D.N., Bordin D.S., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2758
  11. Hall S.N., Appelman H.D. Autoimmune Gastritis. Arch Pathol Lab Med. 2019; 143(11):1327-1331. doi: 10.5858/arpa.2019-0345-RA.
  12. Rodriguez-Castro K.I., Franceschi M., Miraglia C., Russo M., Nouvenne A., Leandro G., et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed. 2018; 89(8-S):100-103. doi: 10.23750/abm.v89i8-S.7919.
  13. Лосик Е.А., Селиванова Л.С., Антонова Т.В., Лапина Т.Л., Тертычный А.С., Ивашкин В.Т. Морфологические критерии диагноза аутоиммунного гастрита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(5):13-20. doi:10.22416/1382-4376-2016-26-5-13-20. Losik Y.A., Selivanova L.S., Antonova T.V., Lapina T.L., Tertychny A.S., Ivashkin V.T. Morphological diagnostic criteria of autoimmune gastritis. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(5):13-20. (In Russ.) https://doi.org/10.22416/1382-4376-2016-26-5-13-20
  14. Bordin D., Morozov S., Plavnik R., Bakulina N., Voynovan I., Skibo I. et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022 ;27(5):e12924. doi: 10.1111/hel.12924.
  15. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996; 20(10):1161-81. doi: 10.1097/00000478-199610000-00001.
  16. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M. et al. H. pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345:784–9. doi: 10.1056/NEJMoa001999.
  17. Meining A., Bayerdörffer E., Müller P. et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998; 432(4):311–14. doi: 10.1007/s004280050171.
  18. Miehlke S., Hackelsberger A., Meining A., Hatz R., Lehn N.,  Malfertheiner P. et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer. 1998; 78(2):263–6. doi: 10.1038/bjc.1998.475.
  19. Rugge M., Meggio A., Pennelli G., Piscioli F., Giacomelli L.,  De Pretis G. et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007; 56(5): 631–636. doi: 10.1136/gut.2006.106666.
  20. Аруин Л.И., Кононов А.В., Мозговой С.И. Международная классификация хронического гастрита: что следует принять и что вызывает сомнения. Архив патологии. 2009; 71(4):11-18.
  21. Кононов А.В., Потрохова Е.А., Мозговой С.И., Поморгайло Е.Г., Новиков Д.Г. Новая медицинская технология «Молекулярно-генетическая методика прогноза и патоморфологический мониторинг риска развития рака желудка кишечного типа при Helicobacter pylori-инфекции», разрешение Федеральной службы в сфере здравоохранения и социального развития № 2010/220 от 10 июня 2010 г., серия АА 0000001.
  22. Capelle L.G., de Vries A.C., Haringsma J., Borg F.T., de Vries R.A., Bruno M. et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. GastrointestEndosc. 2010; 71(7):1150-1158. doi: 10.1016/j.gie.2009.12.029.
  23. Kimura K., Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(3):87–97. doi: 10.1055/s-0028-1098086.
  24. Miwata T., Quach D.T., Hiyama T., Aoki R., Le H.M., Tran P.L. et al. Interobserver and intraobserver agreement for gastric mucosa atrophy. BMC Gastroenterol. 2015; 15:95. doi: 10.1186/s12876-015-0327-x.
  25. Song J.H., Kim S.G., Jin E.H., Lim J.H., Yang S.Y. Risk Factors for Gastric Tumorigenesis in Underlying Gastric Mucosal Atrophy. Gut Liver. 2017; 11(5):612-619. doi: 10.5009/gnl16488.
  26. Pimentel-Nunes P., Libânio D., Lage J., Abrantes D., Coimbra M., Esposito G. et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy. 2016; 48(8):723-30. doi: 10.1055/s-0042-108435.
  27. Кононов А.В., Мозговой С.И., Шиманская А.Г. Прижизненная патолого-анатомическая диагностика болезней органов пищеварительной системы. Клинические рекомендации Российского общества патологоанатомов. Практическая медицина. 2019.
  28. Ивашкин В.Т., Маев И.В., Царьков П.В., Королев М.П., Андреев Д.Н., Баранская Е.К., и соавт. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Рос журн гастроэнтерол гепатол колопроктол. 2020;30(1):49-70. doi:10.22416/1382-4376-2020-30-1-49-70. Ivashkin V.T., Maev I.V., Tsar’kov P.V., Korolev M.P., Andreev D.N., Baranskaya E.K., et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Rus J Gastroenterol Hepatol Coloproctol. 2020;30(1):49-70. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-1-49-70
  29. Carabotti M., Lahner E., Esposito G., Sacchi M.C., Severi C., Annibale B. Upper gastrointestinal symptoms in autoimmune gastritis: A cross-sectional study. Medicine (Baltimore). 2017; 96(1):e5784. doi:10.1097/MD.0000000000005784.
  30. Miceli E., Lenti M.V., Padula D., Luinetti O., Vattiato C., Monti C.M. et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):812-4. doi: 10.1016/j.cgh.2012.02.018.
  31. Tenca A., Massironi S., Pugliese D., Consonni D., Mauro A., Cavalcoli F. et al. Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring. NeurogastroenterolMotil. 2016; 28(2):274-80. doi:10.1111/nmo.12723. 
  32. Pruthi H.S., Sharma S.K., Singh B., Anand A.C. AETIOLOGY OF UPPER GASTROINTESTINAL HAEMORRHAGEAN ENDOSCOPIC STUDY. Med J Armed Forces India. 2000; 56(3):188-191. doi:10.1016/S0377-1237(17)30162-4.
  33. Biecker E. Diagnosis and therapy of non-variceal upper gastrointestinal bleeding. World J Gastrointest Pharmacol Ther. 2015; 6(4):172-82. doi: 10.4292/wjgpt.v6.i4.172. 
  34. Лосик Е.А., Ивашкин В.Т. Гематологические проявления аутоиммунного гастрита. Рос журн гастроэнтерол гепатол колопроктол. 2016;26(1):37-43. doi:10.22416/1382-4376-2016-26=1-37-43. Losik Y.A., Ivashkin V.T. Hematological manifestations of autoimmune gastritis. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(1):37-43. (In Russ.) https://doi.org/10.22416/1382-4376-2016-26-1-37-43
  35. Rusak E., Chobot A., Krzywicka A., Wenzlau J. Anti-parietal cell antibodies - diagnostic significance. Adv Med Sci. 2016; 61(2):175-179. doi: 10.1016/j.advms.2015.12.004.
  36. Lahner E., Norman G.L., Severi C., Encabo S., Shums Z., Vannella L. et al.  Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009; 104(8):2071-9. doi: 10.1038/ajg.2009.231. 
  37. Huang Y.K., Yu J.C., Kang W.M., Ma Z.-Q., Ye X., Tian S.-B. et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One. 2015; 10(11):e0142080. doi: 10.1371/journal.pone.0142080.
  38. Zagari R.M., Rabitti S., Greenwood D.C.,  Eusebi L.H., Vestito A., Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum as- says for the diagnosis of atrophic gastritis. Aliment PharmacolTher. 2017; 46(7):657 – 667. doi: 10.1111/apt.14248.
  39. Watabe H., Mitsushima T., Yamaji Y., Okamoto M., Wada R., Kokubo T. et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005; 54(6):764–8. doi: 10.1136/gut.2004.055400.
  40. Kurilovich S., Belkovets A., Reshetnikov O., Openko T., Malyutina S., Ragino Y. et al. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res. 2016; 36(1):247-53. PMID: 26722050.
  41. Pimentel-Nunes P., Libânio D., Marcos-Pinto R., Areia M., Leja M., Esposito G. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de EndoscopiaDigestiva (SPED) guideline update 2019. Endoscopy. 2019; 51(4):365-388. doi: 10.1055/a-0859-1883.
  42. Banks M., Graham D., Jansen M., Gotoda T., Coda S., di Pietro M. et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019; 68(9):1545-1575. doi: 10.1136/gutjnl-2018-318126.
  43. Zhao Z., Yin Z., Wang S., Wang J., Bai B., Qiu Z. et al. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J GastroenterolHepatol. 2016; 31(9): 1539 – 1545. doi: 10.1111/jgh.13313.
  44. Ang T.L., Pittayanon R., Lau J.Y., Rerknimitr R., Ho S.H., Singh R. et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J GastroenterolHepatol. 2015; 27(12):1473 – 1478. doi: 10.1097/MEG.0000000000000478.
  45. Kikuste I., Marques-Pereira R., Monteiro-Soares M., Pimentel-Nunes P., Areia M., Leja M. et al. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. Scand J Gastroenterol. 2013; 48(10):1108 – 1117. doi: 10.3109/00365521.2013.825315.
  46. Pimentel-Nunes P., Dinis-Ribeiro M., Soares J.B.,  Marcos-Pinto R., Santos C., Rolandaet C. et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endoscopy. 2012; 44(3): 236 – 246. doi:10.1055/s-0031-1291537.
  47. East J.E., Vleugels J.L., Roelandt P., Bhandari P., Bisschops R., Dekker E. et al. Advanced endoscopic imaging: European Society of Gastrointestinal Endoscopy (ESGE) Technology Review. Endoscopy. 2016;48(11):1029-1045. doi: 10.1055/s-0042-118087.
  48. Rugge M., Genta R.M., Fassan M., Valentini E., Coati I., Guzzinati S. et al. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. Am J Gastroenterol. 2018; 113(11):1621-1628. doi: 10.1038/s41395-018-0353-8.
  49. Mao X.Y., Xu S.F., Liu Q., Jiang J.X., Zhang H.H., Sang H.M. et al. Anatomical predilection of intestinal metaplasia based on 78,335 endoscopic cases. Saudi J Gastroenterol. 2016; 22(2):154-60. doi: 10.4103/1319-3767.178528.
  50. Kim Y.I., Kook M.C., Cho S.J., Lee J.Y., Kim C.G., Joo J. et al. Effect of biopsy site on detection of gastric cancer high-risk groups by OLGA and OLGIM stages. Helicobacter. 2017; 22(6). doi:10.1111/hel.12442.
  51. Isajevs S., Liepniece-Karele I., Janciauskas D., Moisejevs G., Funka K., Kikuste I. et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol. 2014; 26(5):510 – 513. doi: 10.1097/MEG.0000000000000082.
  52. Varbanova M., Wex T., Jechorek D., Röhl F.W., Langner C., Selgradet M. et al. Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment. J Clin Pathol. 2016; 69(1):19 – 25. doi: 10.1136/jclinpath-2015-202858.
  53. 53.  Lan H.C., Chen T.S., Li A.F., Chang F.Y., Lin H.C. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol. 2012;12:182. doi: 10.1186/1471-230X-12-182.
  54. Shin C.M., Kim N., Lee H.S., Lee H.E., Lee S.H., Park Y.S. et al. Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and/or intestinal metaplasia. Helicobacter. 2009;14(6):512-9. doi: 10.1111/j.1523-5378.2009.00726.x. 
  55. Best L.M., Takwoingi Y., Siddique S., Selladurai A., Gandhi A., Low B. et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018; 3(3):CD012080. doi: 10.1002/14651858.CD012080.pub2.
  56. Abd Rahim M.A., Johani F.H., Shah S.A., Hassan M.R., Abdul Manaf M.R. 13C-Urea Breath Test Accuracy for Helicobacter pylori Infection in the Asian Population: A Meta-Analysis. Ann Glob Health. 2019;85(1):110. doi: 10.5334/aogh.2570. 
  57. Lan H.C., Chen T.S., Li A.F., Chang F.Y., Lin H.C. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol. 2012;12:182. doi: 10.1186/1471-230X-12-182.
  58. Shin C.M., Kim N., Lee H.S., Lee H.E., Lee S.H., Park Y.S. et al. Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and/or intestinal metaplasia. Helicobacter. 2009;14(6):512-9. doi: 10.1111/j.1523-5378.2009.00726.x. 
  59. Hsu W.H., Wang S.S., Kuo C.H., Chen C.Y., Chang C.W., Hu H.M. et al. Dual specimens increase the diagnostic accuracy and reduce the reaction duration of rapid urease test. World J Gastroenterol. 2010;16(23):2926-30. doi: 10.3748/wjg.v16.i23.2926.
  60. Yakoob J., Jafri W., Abid S., Jafri N., Abbas Z., Hamid S. et al. Role of rapid urease test and histopathology in the diagnosis of Helicobacter pylori infection in a developing country. BMC Gastroenterol. 2005; 5:38. doi: 10.1186/1471-230X-5-38.
  61. Bordin D.S., Voynovan I.Nю, Andreev D.N., Maev I.V. Current Helicobacter pylori Diagnostics. Diagnostics (Basel). 2021 Aug 12;11(8):1458. doi: 10.3390/diagnostics11081458.
  62. Chung W.C., Jung S.H., Oh J.H., et al. Dual-Priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection. World J Gastroenterol 2014;20:6547–53.
  63. Chung W.C., Jeon E.J., Oh J.H., et al. Dual-Priming oligonucleotide-based multiplex PCR using tissue samples from the rapid urease test kit for the detection of Helicobacter pylori in bleeding peptic ulcers. Dig Liver Dis 2016;48:899–903.
  64. Chen T., Meng X., Zhang H., Tsang R.W., Tsang T.K. Comparing Multiplex PCR and Rapid Urease Test in the Detection of H. pylori in Patients on Proton Pump Inhibitors. Gastroenterol Res Pract. 2012;2012:898276. doi: 10.1155/2012/898276.
  65. Gatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004;99:823–9.
  66. MÄki M., SÖderstrÖm D., Paloheimo L., Hendolin P., Suovaniemi O., SyrjÄnen K. Helicobacter pylori (Hp) IgG ELISA of the New-Generation GastroPanel® Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients. Anticancer Res. 2020;40(11):6387-6398. doi: 10.21873/anticanres.14660.
  67. Gisbert J.P., Pajares J.M. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004;9:347–68.
  68. Ливзан М. А., Кононов А.В., Мозговой С.И. Течение хронического гастрита, ассоциированного с Helicobacter pylori в постэрадикационном периоде. Экспериментальная и клиническая фармакология. 2007; 5:116–123.
  69. Кононов А.В., Мозговой С.И., Ливзан М.А. и соавт. Морфология поверхностного и атрофического хронического гастрита при эрадикации Helicobacter pylori. Архив патологии. 2005; 3:17-21.
  70. Kyzekova J., Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology. 1999; 46(27):2048-56.
  71. Abdul Rasheed Z., Gautam S., Ukabam S., Nayal S. Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. Digestion. 1999;60(3):286-97. doi: 10.1159/000007673.
  72. Genta R.M., Lew G.M., Graham D.Y. Changes in gastric mucosa following eradication of Helicobacter pylori. Mod Pathol.1993;6(3):281–9.
  73. Rugge, M., Sugano, K., Sacchi, D. et al. Gastritis: An Update in 2020. Curr Treat Options Gastro. 2020; 18: 488–503. doi:10.1007/s11938-020-00298-8.
  74. Wang J., Xu L., Shi R., Huang X., Li S.W.H., Huang Z. et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011; 83(4):253–60. doi: 10.1159/000280318.
  75. Rokkas T., Pistolias D., Sechopoulos P., Robotis I., Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007; 12:32–8. doi: 10.1111/j.1523-5378.2007.00563.x.
  76. Kong Y.J., Yi H.G., Dai J.C., Wei M.-X. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2014; 20(19):5903–11. doi: 10.3748/wjg.v20.i19.5903.
  77. Ko S.W., Kim Y.-J., Chung W.C., Lee S.J. Bismuth supplements as the first‐line regimen for Helicobacter pylori eradication therapy: Systemic review and meta‐analysis. Helicobacter. 2019;e12565. https://doi. org/10.1111/hel.12565
  78. McNicholl A.G., Bordin D.S., Lucendo A., Fadeenko G., Fernandez M.C., Voynovan I., et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98. doi: 10.1016/j.cgh.2019.03.048.
  79. Nyssen O.P., Bordin D., Tepes B., Pérez-Aisa Á., Vaira D., Caldas M., et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54. doi: 10.1136/gutjnl-2020-321372.
  80. Yang X., Wang J.X., Han S.X., Gao C.P. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019 ;98(7):e14396. doi: 10.1097/MD.0000000000014396. 
  81. Guo B., Cao N.W., Zhou H.Y., Chu X.J., Li B.Z. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog. 2021;152:104661. doi: 10.1016/j.micpath.2020.104661.
  82. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол. 2018;28(1):55-70. https://doi.org/10.22416/1382-4376-2018-28-1-55-70 Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya Y.K., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctology. 2018;28(1):55-70. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-1-55-70
  83. Хлынов И.Б., Акименко Р.И., Воронова Е.И., Гаранина Е.В., Гурикова И.А., Лосева М.Э., и совт. Роль Lactobacillus reuteri DSMZ17648 в эрадикационной терапии инфекции Helicobacter pylori у взрослых в реальной клинической практике. Лечащий врач. 2020;2:19-22 Khlynov I.V., Akimenko R.I., Voronova E.I., Garanina E.V., Gurikova I.A., Loseva M.E. et al. Possible role of Lactobacillus reuteri for eradication of Helicobacter pylori in adults in real clinical practice. Lechashchy vrach. 2020;2:19-22
  84. Алексеенко С.А., Агеева Е.А. Сравнительная оценка эффективности 10-дневных схем эрадикации Helicobacter pylori инфекции (тройной и тройной с добавлением висмута трикалия дицитрата). Дальневосточный медицинский журнал. 2019;4:62-65 doi:10.35177/1994-5191-2019-4-62-65 [Alekseenko S.A., Ageeva E.A. Comparative evaluation of efficacy of 10-day regimens of Helicobacter pylori infection eradication (triple and triple with the addition bismuth tripotassium dicitrate. Far East Medical J. 2019;4:62-65 doi:10.35177/1994-5191-2019-4-62-65]
  85. Белковец А.В., Курилович С.А., Юркова Т.А., Толкачева Н.Ю., Щербакова Л.В. Сравнительное исследование двух схем эрадикации Helicobacter pylori (с висмутом трикалия дицитратом и без него). Фарматека. 2019;26(2):61–67. DOI: https: //dx.doi. org/10.18565/pharmateca.2019.2.61-67 Belkovets A.V., Kurilovich S.A., TYurkova.A., Tolkacheva N.Yu., Scherbakova L.V. Comparative evaluation of two Helicobacter pylori eradication schemes (with and without bismuth tripotassium dicitrate)Farmateka. 2019;26(2):61–67. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.2.61-67
  86. Сафина Д.Д., Абдулхаков С.Р., Маркелова М.И., Григорьева Т.В., Хуснутдинова Д.Р., Булыгина Е.А., и соавт. Эрадикационная терапия Helicobacter pylori и микробиота кишечника у пациентов с заболеваниями верхних отделов желудочно-кишечного тракта. Вестник современной клинической медицины. 2020;13(1):46-53 DOI: 10.20969/VSKM.2020.13(1).46-53 Safina D.D., Abdulhakov S.R., Markelova M.I., Grigoryeva T.V., Khusnutdinova D.R., Bulygina E.A., et al. Helicobacter pylori eradication therapy and gut microbiota composition in patients with various diseases of upper gastrointestinal tract. The Bulletin of Contemporary Clinical Medicine. 2020; 13 (1): 46-53. DOI:10.20969/VSKM.2020.13(1).46-53
  87. Yuan Y., Ford A.C., Khan K.J., Gisbert J.P., Forman D., Leontiadis G.I., et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337.
  88. Villoria A., Garcia P., Calvet X., Gisbert J.P., Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28:868–77.
  89. Gao W., Zhang X., Yin Y., Yu S., Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol. 2021;35:20587384211030397. doi: 10.1177/20587384211030397.
  90. Tang H.L., Li Y., Hu Y.F., Xie H.G., Zhai S.D. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162
  91. Jung Y.S., Kim E.H., Park C.H. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106-114. doi: 10.1111/apt.14130.
  92. Shinozaki S., Kobayashi Y., Osawa H., Sakamoto H., Hayashi Y., Lefor A.K., Yamamoto H. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis. Digestion. 2021;102(3):319-325. doi: 10.1159/000504939.
  93. Nishizawa T., Nishizawa Y., Yahagi N., Kanai T., Takahashi M., Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014; 29(4):20-24. doi:10.1111/jgh.12769.
  94. Andreev D.N., Maev I.V., Dicheva D.T. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pyloriInfection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. doi: 10.3390/jcm8091498.
  95. Андреев Д.Н., Маев И.В., Бордин Д.С., Лямина С.В., Дичева Д.Т., Фоменко А.К., Багдасарян А.С. Эффективность включения ребамипида в схемы эрадикационной терапии инфекции Helicobacter pyloriв России: метаанализ контролируемых исследований. Consilium Medicum. 2022;24(5):333-338. doi: 10.26442/20751753.2022.5.201863 Andreev D.N., Maev I.V., Bordin D.S., Lyamina S.V., Dicheva D.T., Fomenko A.K., Bagdasarian A.S. Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: a meta-analysis of controlled trials. Consilium Medicum. 2022;24(5):333-338. doi: 10.26442/20751753.2022.5.201863
  96. Graham D.Y., Lew G.M., Malaty H.M., Evans D.G., Evans D.J. Jr., Klein P.D., et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102(2):493-6
  97. Kim B.J., Lee H., Lee Y.C., Jeon S.W., Kim G.H., Kim H.S. et al. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13(5):531-540. doi: 10.5009/gnl19136.
  98. Минушкин О., Зверков И., Володин Д., Иванова О., Шулешова А. Эффективность препарата "Пилобакт AM" в эрадикационной терапии язвенной болезни двенадцатиперстной кишки. Врач. 2008; 5: 67–69. [Minushkin O., Zverkov I., Volodin D., Ivanova O., Shuleshova A. Effektivnost" preparata "Pilobakt AM" v eradikatsiоnnоi terapii yazvennoi bolezni dvenadtsatiperstnoi kishki. Vrach. 2008; 5: 67–69 (in Russ.)].
  99. McFarland L.V., Malfertheiner P., Huang Y., Wang L. Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World J Meta-Anal. 2015; 3 (2): 97-117 DOI: 10.13105/wjma.v3.i2.97.
  100. Zhou B.G., Chen L.X., Li B., Wan L.Y., Ai Y.W. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019; 24 (5): e12651. DOI: 10.1111/hel.12651.
  101. McFarland L.V., Huang Y., Wang L., Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016; 4 (4):     546-561. DOI: 10.1177/2050640615617358.
  102. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010; 32 (9): 1069-1079. DOI: 10.1111/j.1365-2036.2010.04457.x.
  103. Szajewska H., Horvath A., Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015 ;41 (12): 1237-1245. DOI: 10.1111/apt.13214.
  104. Dang Y., Reinhardt J.D., Zhou X., Zhang G.. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One. 2014; 9 (11): e111030. DOI: 10.1371/journal.pone.0111030.
  105. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015;9(3):707-716. DOI: 10.3892/etm.2015.2174.
  106. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-53. DOI: 10.4321/s1130-01082013000800002.
  107. Goodman C., Keating G., Georgousopoulou E., Hespe C,. Levett K. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021; 11 (8): e043054. DOI: 10.1136/bmjopen-2020-04305.
  108. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017; 12 (12):CD006095. DOI: 10.1002/14651858.CD006095.
  109. Cárdenas P.A., Garcés D., Prado-Vivar B., Flores N., Fornasini M., Cohen H., Salvador I., Cargua O., Baldeón M.E. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis. 2020; 39 (7):1365-1372. doi: 10.1007/s10096-020-03854-3.
  110. Seddik H., Boutallaka H., Elkoti I., Nejjari F., Berraida R., Berrag S., Loubaris K., Sentissi S., Benkirane A. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol. 2019; 75 (5): 639-645. DOI: 10.1007/s00228-019-02625-0.
  111. Parth K., Prudhivi R., Palatheeya S., Abbas S. K., Varsha K., Niharika B. V., Lyngkhoi B. Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy. J Pharm Res Int. 2021; 33(52B): 151–159. doi: 10.9734/jpri/2021/v33i52B33611.
  112. Martín R., Langella P. Emerging Health Concepts in the Probiotics Field: Streamlining the Definitions. Front Microbiol. 2019;10:1047. doi:10.3389/fmicb.2019.01047
  113. Shenderov B.A. Metabiotics: novel idea or natural development of probiotic conception. Microb Ecol Health Dis. 2013; doi:10.3402/mehd.v24i0.20399
  114. Chang Y.L., Tung Y.C., Tu Y.K., Yeh H.Z., Yang J.C., Hsu P.I. et al. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020;7(1):e000472. doi: 10.1136/bmjgast-2020-000472.
  115. Han Z., Li Y., Kong Q., Liu J., Wang J., Wan M., et al. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis. Helicobacter. 2022;27(6):e12930. doi: 10.1111/hel.12930. 
  116. Gisbert J.P., Romano M., Gravina A.G., Solís-Muñoz P., Bermejo F., Molina-Infante J., Castro-Fernández M. et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41(8):768-75. doi: 10.1111/apt.13128.
  117. Yeo Y.H., Hsu C.C., Lee C.C., Ho H.J., Lin J.T., Wu M.S., et al. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol. 2019;34(1):59-67. doi: 10.1111/jgh.14462.
  118. Mori H., Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol. 2020;26(15):1733-1744. doi: 10.3748/wjg.v26.i15.1733.
  119. Du Y., Bai Y., Xie P., Fang J., Wang X., Hou X. et al. Chronic gastritis in China: a national multi-center survey. BMC Gastroenterol. 2014; 14:21. doi: 10.1186/1471-230X-14-21.
  120. Hawkey C.J., Wilson I., Naesdal J., Långström G., Swannell A.J., Yeomans N.D. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51(3):344-50. doi: 10.1136/gut.51.3.344.
  121. Ng F.H., Wong S.Y., Lam K.F., Chu W.M., Chan P., Ling Y.H. et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010; 138(1):82–88. doi: 10.1053/j.gastro.2009.09.063.
  122. Wilson I., Långström G., Wahlqvist P., Walan A., Wiklund I., Naesdal J. Management of gastroduodenal ulcers and gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drug therapy: A summary of four comparative trials with omeprazole, ranitidine, misoprostol, and placebo. Current therapeutic research. 2001; 62(12):835-850.
  123. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. Мартынов А.И., Яхно Н.Н., Арутюнов Г.П., и соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1-29. Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N., Arutyunov G.P., et al. RATIONAL USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. CLINICAL GUIDELINES. Rheumatology Science and Practice. 2018;56:1-29. (In Russ.) https://doi.org/10.14412/1995-4484-2018-1-29
  124. Du Y., Li Z., Zhan X., Chen J., Gao J., Gong Y. et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. DigDisSci. 2008;53(11):2886-95. doi: 10.1007/s10620-007-0180-z.
  125. Kim G.H., Lee H.L., Joo M.K., Park H.J., Jung S.W., Lee O.J. et al. Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double- Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study. GutLiver. 2021; doi: 10.5009/gnl20338.
  126. Кононов А.В., Мозговой С.И., Рыбкина Л.Б., Бунова С.С., Шиманская А.Г. Оценка цитопротективного влияния висмута трикалия дицитрата на слизистую оболочку желудка при эрадикации H. pylori и пролонгированном приеме препарата. Рос журн гастроэнтерол гепатол колопроктол. 2006; 16(6):21-28. Kononov A.V., Mozgovoy S.I., Rybkina L.B., Bunova S.S., Shimanskaya A.G. Assessment of bismuth tripotassium dicitrate cytoprotective effect on stomach mucosa at H. pylori eradication and prolonged drug administration. Rus J Gastroenterol Hepatol Coloproctol 2006; 16(6):21-28
  127. Лапина Т.Л. Возможности лекарственного воздействия на цитопротективные свойства гастродуоденальной слизистой оболочки. Рос жур гастроэнтерол гепатол колопроктол. 2006; 16(5):2-7. Lapina T.L. Pharmaceutical options of modulation gastroduodenal mucosa cytoprotection. Rus J Gastroenterol Hepatol Coloproctol. 2006; 16(5):2-7
  128. Han X., Jiang K., Wang B., Zhou L., Chen X., Li S. Effect of rebamipide on the premalignant progression of chronic gastritis: a randomized controlled study. Clin Drug Investig. 2015; 35(10):665 – 673. doi: 10.1007/s40261-015-0329-z.
  129. Kamada T., Sato M., Tokutomi T., Watanabe T., Murao T., Matsumoto H. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015; 2015: 865146 – 86514. doi: 10.1155/2015/865146.
  130. Simadibrata M., Syam A., Rani A., Wanandi S., Fauzi A., Abdullah M. Anti free radical & anti inflammatory effect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013. 3:72-77. doi:10.4236/ojgas.2013.31011.
  131. Lee J.S., Jeon S.W., Lee H.S., Kwon Y.H., Nam S.Y., Bae H.I., Seo A.N. Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Dig Dis Sci. 2022;67(6):2395-2402. doi: 10.1007/s10620-021-07038-7. 
  132. Seo G.H., Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019; 100(4):221-228. doi:10.1159/000495288.
  133. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010; 4(3):261-270. doi: 10.1586/egh.10.25.
  134. Haruma K., Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment PharmacolTher. 2003;18(1):153-15. doi:10.1046/j.1365-2036.18.s1.17.x.
  135. Ford A.C., Tsipotis E., Yuan Y., Leontiadis G.I., Moayyedi P. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. Gut. 2022 gutjnl-2021-326583. doi: 10.1136/gutjnl-2021-326583.
  136. Pinto-Sanchez M.I., Yuan Y., Hassan A., Bercik P., Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194. doi: 10.1002/14651858.CD011194.pub3.
  137. Moayyedi P., Delaney B.C., Vakil N., Forman D., Talley N.J. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127(5):1329-37. doi: 10.1053/j.gastro.2004.08.026.
  138. Ford A.C., Moayyedi P., Black C.J., Yuan Y., Veettil S.K., Mahadeva S., et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther. 2021 Jan;53(1):8-21. doi: 10.1111/apt.16072. 
  139. Oh J.H., Kwon J.G., Jung H.K., Tae C.H., Song K.H., Kang S.J. et al. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J NeurogastroenterolMotil. 2020;26(1):29-50. doi:10.5056/jnm19209.
  140. Stanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J. et al. Gastroduodenal Disorders. Gastroenterology. 2016; 150 (6): 1380-92. doi: 10.1053/j.gastro.2016.02.011.
  141. Pittayanon R., Yuan Y., Bollegala N.P., Khanna R., Leontiadis G.I., Moayyedi P. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev. 2018;10(10):CD009431. doi: 10.1002/14651858.CD009431.pub3.
  142. Xiao G., Xie X., Fan J., Deng J., Tan S., Zhu Y., et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:541950. doi: 10.1155/2014/541950.
  143. Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T. et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17(1):83. doi: 10.1186/s12876-017-0639-0.
  144. Huang X., Lv B., Zhang S., Fan Y.H., Meng L.N. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol. 2012;18(48):7371-7377. doi:10.3748/wjg.v18.i48.7371.
  145. Veldhuyzen van Zanten S.J., Jones M.J., Verlinden M., Talley N.J. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol. 2001;96(3):689-696. doi: 10.1111/j.1572-0241.2001.03521.x.
  146. Tack J., Pokrotnieks J., Urbonas G., Banciu C., Yakusevich V., Bunganic I. et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018;30(6):e13284. doi: 10.1111/nmo.13284. 
  147. Бакулин И.Г., Хлынов И.Б., Саблин О.А., Пахомова И.Г., Павлова Н.В. Клиническая эффективность при- менения акотиамида у пациентов с функциональной диспепсией: результаты многоцентрового исследования. Медицинский совет. 2023;17(13):108–115. https://doi.org/10.21518/ms2023-253.
  148. Mizukami K., Katsuta M., Okamoto K., Fukuda K., Ogawa R., Kawahara Y., et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332-337. doi: 10.3164/jcbn.20-17.
  149. Holtmann G., Talley N. J., Liebregts T., Adam B., Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006; 354(8):832-40. doi: 10.1056/NEJMoa052639.
  150. Ивашкин В. Т., Шептулин А. А., Трухманов А. С. Эффективность применения ганатона (итоприда гидрохлорида) в лечении больных функциональной диспепсией. Фарматека 2009; 13:50-4.
  151. Sawant P, Das HS, Desai N, Kalokhe S, Patil S. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India. 2004;52:626-8.
  152. Zhong Y.Q., Zhu J., Guo J.N., Yan R., Li H.J., Lin Y.H. et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome. ZhonghuaNeiKe Za Zhi. 2007;46(11):899-902
  153. Kountouras J., Gavalas E., Papaefthymiou A., Tsechelidis I., Polyzos S.A., Bor S. et al. Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. Medicina (Kaunas). 2020;56(7):339. doi: 10.3390/medicina56070339.
  154. Кардашева С.С., Картавенко И.М., Максимова Н.Б., Юрьева Е.Ю., Попова И.Р., Павлов Ч.С., Ивашкин В.Т. Эффективность тримебутина малеата в лечении пациентов с функциональной диспепсией: результаты наблюдательного исследования «TREND». Рос журн гастроэнтерол гепатол колопроктол. 2018;28(5):67-76. doi:10.22416/1382-4376-2018-28-5-67-76. Kardasheva S.S., Kartavenko I.M., Maksimova N.B., Yurieva E.Yu., Popova I.R., Pavlov Ch.S., Ivashkin V.T. Efficacy of Trimebutine Maleate (Trimedat®) in the Treatment of Patients with Functional Dyspepsia: Results of the “TREND” Observational Study. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(5):67-76. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-5-67-76
  155. Андреев Д.Н., Маев И.В. Эффективность тримебутина в рамках лечения функциональных заболеваний желудочно-кишечного тракта и желчных путей: наблюдательное многоцентровое исследование. Терапевтический архив. 2021;93(8):897-903. doi: 10.26442/00403660.2021.08.200919 Andreev DN, Maev IV. Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study. Terapevticheskii arkhiv. 2021;93(8):897-903. doi: 10.26442/00403660.2021.08.200919
  156. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment PharmacolTher. 2001;15(3):355-61. doi: 10.1046/j.1365-2036.2001.00937.x.
  157. Карева Е.Н., Сереброва С.Ю., Дроздов В.Н., Кургузова Д.О., Стародубцев А.К., Васильев Н.Н. Современные аспекты безопасности домперидона. Экспериментальная и клиническая фармакология. 2018; 81(9):39-44. https://doi.org/10.30906/0869-2092-2018-81-9-39-44 Modern Aspects of Domperidone Safety
  158. Сюняева Л.А., Шульпекова Н.В., Лапина Т.Л. Диспепсия: терминология, причины и факторы риска, тактика ведения пациентов. Медицинский Совет. 2022;(7):44-51. https://doi.org/10.21518/2079-701X-2022-16-7-44-51 Syunyaeva L.A., Shulpekova N.V., Lapina T.L. Dyspepsia: terminology, causes and risk factors, patient management. Meditsinskiy sovet = Medical Council. 2022;(7):44-51. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-7-44-51
  159. Лялюкова Е.А., Павлова Н.В. Эффективность фиксированной комбинации омепразола и домперидона для лечения пациентов с функциональной диспепсией: результаты исследования TANDEM. Медицинский Совет. 2022;(23):181-190. https://doi.org/10.21518/2079-701X-2022-16-23-181-190 Lyalyukova E.A., Pavlova N.V. Efficacy of omeprazole and domperidone fixed combination in the treatment of patients with functional dyspepsia: results from TANDEM study. Meditsinskiy sovet = Medical Council. 2022;(23):181-190. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-23-181-190
  160. Jaafar M.H., Safi S.Z., Tan M.P., Rampal S., Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018; 63(5):1250-1260. doi: 10.1007/s10620-017-4871-9.
  161. Zhao G., Xue M., Hu Y., Lai S., Chen S., Wang L. How commonly is the diagnosis of gastric low grade dysplasia upgraded following endoscopic resection? A meta-analysis. PLoSOne 2015; 10(7): e0132699. doi: 10.1371/journal.pone.0132699.
  162. Sung J.K. Diagnosis and management of gastric dysplasia. Korean J InternMed. 2016;31(2):201–9. doi: 10.3904/kjim.2016.021.
  163. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol. 1985; 12: 2 – 10
  164. Lauwers G, Carneiro F, Graham D et al. Gastric carcinoma. In: Theise N, ed. WHO Classification of tumours of the digestive system. Lyon: IARC Press; 2010: 48 – 58
  165. Лейзерман В.Г., Бугрова О.В., Красикова С.И. Восстановительная медицина. Феникс. 2008.
  166. Lee Y.C., Chiang T.H., Chou C.K., Tu Y.-K.,  Liao W.-C., Wu M.-S. et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113–1124.e5. doi: 10.1053/j.gastro.2016.01.028.
  167. Ford A.C., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020. doi:10.1136/gutjnl-2020-320839.
  168. Chiang T.H., Chang W.J., Chen S.L., Yen A.M., Fann J.C., Chiu S.Y et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021; 70(2):243-250. doi: 10.1136/gutjnl-2020-322200.
  169. Ma J.L., Zhang L., Brown L.M., Shen L., Pan K.-F., Liu W.-D. et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488–92. doi: 10.1093/jnci/djs003.
  170. Wong B.C.-Y, Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291(2):187–94. doi: 10.1001/jama.291.2.187.
  171. Choi I.J., Kook M.C., Kim Y.I., Cho S.-J., Lee J.Y., Kim C.G. et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018; 378(12):1085 – 1095. doi: 10.1056/NEJMoa1708423.
  172. Bang C.S., Baik G.H., Shin I.S., Kim J.B., Suk K.T., Yoon J.H. et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci. 2015; 30(6): 749 – 756.
  173. Jung D.H., Kim J.H., Chung H.S., Park J.C., Shin S.K., Lee S.K. et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoSOne. 2015; 10(4): e0124725. doi: 10.1371/journal.pone.0124725.
  174. Ивашкин В.Т., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Маев И.В., Драпкина О.М. и соавт. Практические шаги по профилактике рака желудка в Российской Федерации: алгоритм ведения пациентов с хроническим геликобактерным гастритом (Материалы и резолюция совета экспертов 9 декабря 2013 г.) Рос журн гастроэнтерол гепатол колопроктол. 2014; 24 (2):102-4. Ivashkin V.T., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Maev I.V., Drapkina O.M. et al. Practical steps on stomach cancer prevention in the Russian Federation: H. pylori-associated gastritis management algorithm (Advisory board position statement, December, 9, 2013). Rus J Gastroenterol Hepatol Coloproctol. 2014; 24 (2):102-4.
  175. Song H., Ekheden I.G., Zheng Z. et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015; 351: h3867. doi: 10.1136/bmj.h4134.
  176. Rugge M., Meggio A., Pravadelli C., Barbareschi M., Fassan M., Gentilini M. et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019; 68(1): 11 – 17. doi: 10.1136/gutjnl-2017-314600.
  177. Cho S.J., Choi I..J, Kook M.C., Nam B.-H., Kim C.G., Lee J.Y. et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther. 2013; 38(10):1292 – 1302. doi: 10.1111/apt.12515.
  178. Kodama M., Murakami K., Okimoto T., Abe H., Sato R., Ogawa R. et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol. 2013; 48(11): 1249 – 1256. doi: 10.3109/00365521.2013.838994.
  179. Mera R.M., Bravo L.E., Camargo M.C., Bravo J.C., Delgado A.G., Romero-Gallo J. et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018; 67(7):1239 – 1246. doi: 10.1136/gutjnl-2016-311685.
  180. Gonzalez C.A., Sanz-Anquela J.M., Companioni O., Bonet C., Berdasco M., López C. et al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol. 2016; 31(5): 953 – 958. doi: 10.1111/jgh.13249.
  181. Gonzalez C.A., Sanz-Anquela J.M., Gisbert J.P., Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer. 2013; 133(5): 1023 – 1032. doi: 10.1002/ijc.28003.
  182. Conchillo J.M., Houben G., de Bruine A., Stockbrügger R. Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma? Eur J Cancer Prev. 2001; 10(4):307 – 312. doi: 10.1097/00008469-200108000-00003.
  183. Rokkas T., Sechopoulos P., Pistiolas D., Georgios Margantinis, Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2010; 22(9):1128 – 1133. doi: 10.1097/MEG.0b013e3283398d37.
  184. Marcos-Pinto R., Dinis-Ribeiro M., Carneiro F., Wen X., Lopes C., Figueiredo C. et al. First-degree relatives of early-onset gastric cancer patients show a high risk for gas tric cancer: phenotype and genotype profile. Virchows Arch. 2013; 463(3): 391 – 399. doi: 10.1007/s00428-013-1458-5.
  185. Vannella L., Lahner E., Osborn J., Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013; 37(4): 375 – 382. doi: 10.1111/apt.12177.
  186. Sjoblom S.M., Sipponen P., Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut. 1993; 34(1): 28 – 32. doi: 10.1136/gut.34.1.28.
  187. Brinton L.A., Gridley G., Hrubec Z., Hoover R., Fraumeni J.F. Cancer risk following pernicious anaemia. Br J Cancer. 1989; 59(5): 810 – 813. doi: 10.1038/bjc.1989.169.
  188. Kim H.H., Uedo N. What Have We Accomplished in Endoscopic Image Analysis for Atrophic Gastritis? Korean J Helicobacter Upper Gastrointest Research. 2013;13(1):6-19 doi:10.7704/kjhugr.2013.13.1.6
  189. Toyoshima O., Nishizawa T., Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. World J Gastroenterol 2020; 26(5): 466-477. doi:10.3748/wjg.v26.i5.466.
  190. Loffeld R. Diagnostic value of endoscopic signs of gastritis: with special emphasis to nodular antritis //The Netherlands Journal of Medicine. – 1999. – Т. 54. – №. 3. – С. 96-100.
  191. Fischbach L. A. et al. A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country //Helicobacter. – 2009. – Т. 14. – №. 2. – С. 100-108.
  192. Shin K. et al. Second-line bismuth-containing quadruple therapy for Helicobacter pylori infection: A 12-year study of annual eradication rates //Journal of Clinical Medicine. – 2021. – Т. 10. – №. 15. – С. 3273.
  193. Wolfe M. M., Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome //Gastroenterology. – 2000. – Т. 118. – №. 2. – С. S9-S31.
  194. Boparai V., Rajagopalan J., Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients //Drugs. – 2008. – Т. 68. – С. 925-947.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*